The KrasG12D-LSLp53fl/fl mice [53] is one of the most relevant preclinical models of NSCLC since 20-30% of NSCLC patients carry Kras mutation [54] and 35-60% show genetic aberrations in p53 [55]. Here, TP53 is linked to non-small cell lung carcinoma.